Last updated on February 2018

High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation


Brief description of study

This randomized, open-label study is aimed to evaluate the efficacy of high-dose icotinib in treating advanced non-small cell lung cancer patients with positive EGFR 21 exon mutation.

Clinical Study Identifier: NCT02404675

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.